<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB02640</drugbank-id>
  <drugbank-id>EXPT01509</drugbank-id>
  <name>Fumagillin</name>
  <description/>
  <cas-number>23110-15-8</cas-number>
  <unii>7OW73204U1</unii>
  <average-mass>458.551</average-mass>
  <monoisotopic-mass>458.230453435</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Peterson, M.H., Goldstein, A.W. and Denison, F.W. Jr.; U.S. Patent 2,803,586; August 20, 1957; assigned to Abbott Laboratories.</synthesis-reference>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.</description>
    <direct-parent>Medium-chain fatty acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Fatty Acyls</class>
    <subclass>Fatty acids and conjugates</subclass>
    <alternative-parent>Branched fatty acids</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Dicarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Enoate esters</alternative-parent>
    <alternative-parent>Epoxides</alternative-parent>
    <alternative-parent>Epoxy fatty acids</alternative-parent>
    <alternative-parent>Fatty acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Unsaturated fatty acids</alternative-parent>
    <substituent>Aliphatic heteropolycyclic compound</substituent>
    <substituent>Alpha,beta-unsaturated carboxylic ester</substituent>
    <substituent>Branched fatty acid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Dicarboxylic acid or derivatives</substituent>
    <substituent>Enoate ester</substituent>
    <substituent>Epoxy fatty acid</substituent>
    <substituent>Ether</substituent>
    <substituent>Fatty acid ester</substituent>
    <substituent>Heterocyclic fatty acid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Medium-chain fatty acid</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Oxirane</substituent>
    <substituent>Unsaturated fatty acid</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">fumagilina</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Flisint</name>
      <company>Sanofi</company>
    </international-brand>
    <international-brand>
      <name>Fugillin</name>
      <company>Upjohn</company>
    </international-brand>
    <international-brand>
      <name>Furnidil</name>
      <company>Abbott</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Angiogenesis Inhibitors</category>
      <mesh-id>D020533</mesh-id>
    </category>
    <category>
      <category>Angiogenesis Modulating Agents</category>
      <mesh-id>D043924</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Products, Insecticides and Repellents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiprotozoals</category>
      <mesh-id>D000981</mesh-id>
    </category>
    <category>
      <category>Cycloparaffins</category>
      <mesh-id>D003516</mesh-id>
    </category>
    <category>
      <category>Fatty Acids</category>
      <mesh-id>D005227</mesh-id>
    </category>
    <category>
      <category>Growth Inhibitors</category>
      <mesh-id>D006131</mesh-id>
    </category>
    <category>
      <category>Growth Substances</category>
      <mesh-id>D006133</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Terpenes</category>
      <mesh-id>D013729</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes>
    <atc-code code="P01AX10">
      <level code="P01AX">Other agents against amoebiasis and other protozoal diseases</level>
      <level code="P01A">AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES</level>
      <level code="P01">ANTIPROTOZOALS</level>
      <level code="P">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fumagillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fumagillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Fumagillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fumagillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Pamidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Clodronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Risedronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Tiludronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06255</drugbank-id>
      <name>Incadronic acid</name>
      <description>The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Incadronic acid.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.61</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.30e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2E,4E,6E,8E)-10-{[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl]oxy}-10-oxodeca-2,4,6,8-tetraenoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>fumagillin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>458.551</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>458.230453435</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C26H34O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C26H34O7/c1-18(2)13-14-20-25(3,33-20)24-23(30-4)19(15-16-26(24)17-31-26)32-22(29)12-10-8-6-5-7-9-11-21(27)28/h5-13,19-20,23-24H,14-17H2,1-4H3,(H,27,28)/b7-5+,8-6+,11-9+,12-10+/t19-,20-,23-,24-,25+,26+/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NGGMYCMLYOUNGM-CSDLUJIJSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>97.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>128.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>51.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>190-192</value>
      <source>Peterson, M.H., Goldstein, A.W. and Denison, F.W. Jr.; U.S. Patent 2,803,586; August 20, 1957; assigned to Abbott Laboratories.</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8516</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>48635</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6917655</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505331</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C09668</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5292885</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50113436</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>FUG</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DNC000664</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Fumagillin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL32838</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001534</id>
      <name>Methionine aminopeptidase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P50579" source="Swiss-Prot">
        <name>Methionine aminopeptidase 2</name>
        <general-function>Poly(a) rna binding</general-function>
        <specific-function>Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo.Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis.</specific-function>
        <gene-name>METAP2</gene-name>
        <locus>12q22</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.57</theoretical-pi>
        <molecular-weight>52891.145</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16672</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>METAP2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U29607</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>903982</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1573</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P50579</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MAP2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.11.18</synonym>
          <synonym>Initiation factor 2-associated 67 kDa glycoprotein</synonym>
          <synonym>MAP 2</synonym>
          <synonym>MNPEP</synonym>
          <synonym>p67</synonym>
          <synonym>P67EIF2</synonym>
          <synonym>Peptidase M</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0003046|Methionine aminopeptidase 2
MAGVEEVAASGSHLNGDLDPDDREEGAASTAEEAAKKKRRKKKKSKGPSAAGEQEPDKES
GASVDEVARQLERSALEDKERDEDDEDGDGDGDGATGKKKKKKKKKRGPKVQTDPPSVPI
CDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVR
KYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTT
VLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDV
GEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEV
YAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWL
DRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020537|Methionine aminopeptidase 2 (METAP2)
ATGGCGGGTGTGGAGGAGGTAGCGGCCTCCGGGAGCCACCTGAATGGCGACCTGGATCCA
GACGACAGGGAAGAAGGAGCTGCCTCTACGGCTGAGGAAGCAGCCAAGAAAAAAAGACGA
AAGAAGAAGAAGAGCAAAGGGCCTTCTGCAGCAGGGGAACAGGAACCTGATAAAGAATCA
GGAGCCTCAGTGGATGAAGTAGCAAGACAGTTGGAAAGATCAGCATTGGAAGATAAAGAA
AGAGATGAAGATGATGAAGATGGAGATGGCGATGGAGATGGAGCAACTGGAAAGAAGAAG
AAAAAGAAGAAGAAGAAGAGAGGACCAAAAGTTCAAACAGACCCTCCCTCAGTTCCAATA
TGTGACCTGTATCCTAATGGTGTATTTCCCAAAGGACAAGAATGCGAATACCCACCCACA
CAAGATGGGCGAACAGCTGCTTGGAGAACTACAAGTGAAGAAAAGAAAGCATTAGATCAG
GCAAGTGAAGAGATTTGGAATGATTTTCGAGAAGCTGCAGAAGCACATCGACAAGTTAGA
AAATACGTAATGAGCTGGATCAAGCCTGGGATGACAATGATAGAAATCTGTGAAAAGTTG
GAAGACTGTTCACGCAAGTTAATAAAAGAGAATGGATTAAATGCAGGCCTGGCATTTCCT
ACTGGATGTTCTCTCAATAATTGTGCTGCCCATTATACTCCCAATGCCGGTGACACAACA
GTATTACAGTATGATGACATCTGTAAAATAGACTTTGGAACACATATAAGTGGTAGGATT
ATTGACTGTGCTTTTACTGTCACTTTTAATCCCAAATATGATACGTTATTAAAAGCTGTA
AAAGATGCTACTAACACTGGAATAAAGTGTGCTGGAATTGATGTTCGTCTGTGTGATGTT
GGTGAGGCCATCCAAGAAGTTATGGAGTCCTATGAAGTTGAAATAGATGGGAAGACATAT
CAAGTGAAACCAATCCGTAATCTAAATGGACATTCAATTGGGCAATATAGAATACATGCT
GGAAAAACAGTGCCGATTGTGAAAGGAGGGGAGGCAACAAGAATGGAGGAAGGAGAAGTA
TATGCAATTGAAACCTTTGGTAGTACAGGAAAAGGTGTTGTTCATGATGATATGGAATGT
TCACATTACATGAAAAATTTTGATGTTGGACATGTGCCAATAAGGCTTCCAAGAACAAAA
CACTTGTTAAATGTCATCAATGAAAACTTTGGAACCCTTGCCTTCTGCCGCAGATGGCTG
GATCGCTTGGGAGAAAGTAAATACTTGATGGCTCTGAAGAATCTGTGTGACTTGGGCATT
GTAGATCCATATCCACCATTATGTGACATTAAAGGATCATATACAGCGCAATTTGAACAT
ACCATCCTGTTGCGTCCAACATGTAAAGAAGTTGTCAGCAGAGGAGATGACTATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00557</identifier>
            <name>Peptidase_M24</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aminopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloaminopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloexopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>poly(A) RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>N-terminal protein amino acid modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-methionine modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein initiator methionine removal</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of rhodopsin mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhodopsin mediated signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>